|
Human and Animal Cells
|
SLVL(RCB1702)
|
54875
|
Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
|
Br J Haematol |
2019-4-1 |
Pubmed
Full text
|
